Vizgen’s Certified Service Partner Program Extends to Partners for Spatial Proteomics

CAMBRIDGE, Mass., October 15, 2025 – Vizgen’s CSP program was first launched in December 2024 with an inaugural network of CSPs. The partners who become CSPs in this program are certified academic and commercial services organizations, with the training, expertise and technology infrastructure required to provide full-service Vizgen solutions for breakthrough discoveries. The initial set of partners has been laser-focused on offering researchers access to Vizgen’s transformative MERSCOPE® platform and MERFISH 2.0™ chemistry.

In this next phase of the CSP program, Vizgen is broadening access and support for its pathology-grade spatial proteomics solutions, as a result of the merger with Ultivue, with industry-leading clinically accepted operational standards. By collaborating with clinical research industry leaders, Vizgen aims to empower pathologists, clinicians and researchers with its InSituPlex® assays, OmniVUE™ and U-VUE® panels, and STARVUE™ image data science platform in support of robust high-throughput biomarker strategies to evaluate specific biological hypotheses with high precision.

Among the first CSPs in Vizgen’s program expansion for spatial proteomics are HistologiX, Lanterne Dx (LDX), HistoWiz and Arkana Laboratories.

HistologiX

HistologiX is a leading GLP/GCP compliant CRO supporting tissue-based evaluation of biomarkers. Their scientific team provides bespoke, specialist histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), multiplex in situ hybridization (ISH), using RNAScope, digital pathology, and image analysis services.

Morag McFarlane, PhD, Chief Executive Officer at HistologiX shared, “We’re excited to join the CSP program at Vizgen. As a GLP/GCP compliant CRO specializing in tissue-based biomarker analysis, InSituPlex and STARVUE have significantly advanced our exploration of the tumor-immune microenvironment, helping our clients understand the impact of their therapies. The ready-to-use configurable OmniVUE panels provide robust, high-quality data with a streamlined workflow, while preserving tissue integrity. Vizgen’s comprehensive spatial proteomics solutions provide valuable and actionable intelligence in our mission to support the development of novel immunotherapies.”

Lanterne Dx

Lanterne Dx (LDX) is a full-service histopathology CRO, offering discovery, translational, and clinical biomarker services. As a CAP-CLIA accredited provider, LDX specializes in biomarker development, including antibody development, optimization, and validation.

“At Lanterne Dx, we share a common vision with Vizgen to offer expert guidance and solutions as a trusted partner throughout the drug development journey, from pre-clinical research to translational studies and into clinical research applications. Being part of Vizgen’s CSP program, with a focus on spatial proteomics, gives our joint customers advantages that help streamline and accelerate drug development efforts. As a CAP-CLIA accredited provider, LDX specializes in biomarker development, including antibody development, optimization and validation,” said Jon Bishop, Founder and Chief Executive Officer at Lanterne Dx.

HistoWiz

HistoWiz is a provider of automated, high-quality histology and digital pathology services with industry-leading turnaround times. HistoWiz empowers researchers to quickly process tissue samples, digitize slides for instant viewing and management, and collaborate seamlessly.

Patrick Savickas, Head of Scientific Development at HistoWiz said, “We’re proud to be part of Vizgen’s CSP program, leveraging the powerful spatial proteomics solutions that became part of Vizgen’s product portfolio with the merger with Ultivue. By collaborating with the team at Vizgen, we are able to offer significant value to our customers, accelerating scientific discovery and drug development.”

Arkana Laboratories

Arkana Laboratories is the largest renal pathology practice in the United States, currently serving more than 3,000 nephrologists in 46 states and the District of Columbia and processing nearly 30,000 renal biopsies per year, representing approximately 35-40% of all medical kidney biopsies performed in the United States. Arkana has processed over 260,000 renal biopsies since its start of business in 2001.

“Spatial proteomics is a scientific innovation that has the potential to improve the understanding of diseases and help guide the development of more impactful healthcare solutions in the future. Our inclusion in Vizgen’s CSP program ensures that we can match our best-in-class research services with best-in-class spatial proteomics tools and technologies,” said Jason Paris, Director of Contract Research at Arkana Laboratories.

Overall, these new CSP partners play an important role in expanding access to Vizgen’s powerful portfolio of spatial proteomics tools, ensuring consistent, high-quality results through a rigorous certification process. The extension of this CSP program also offers partners access to co-marketing benefits and the opportunity to more deeply collaborate with Vizgen on advancing the field of spatial proteomics.

To learn more about Vizgen’s CSP Program and become our Certified Service Partner, visit https://ultivue.com/partners/